[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT832094E - Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos - Google Patents

Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos

Info

Publication number
PT832094E
PT832094E PT96922490T PT96922490T PT832094E PT 832094 E PT832094 E PT 832094E PT 96922490 T PT96922490 T PT 96922490T PT 96922490 T PT96922490 T PT 96922490T PT 832094 E PT832094 E PT 832094E
Authority
PT
Portugal
Prior art keywords
compounds
inhibitors
evaluating
methods
processes
Prior art date
Application number
PT96922490T
Other languages
English (en)
Inventor
Michael Zasloff
Jon Williams
Mark Anderson
Michael Mclane
Steven Jones
William A Kinney
Ann Shinnar
Meena N Rao
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/476,855 external-priority patent/US5874597A/en
Priority claimed from US08/475,572 external-priority patent/US5840936A/en
Priority claimed from US08/479,457 external-priority patent/US5763430A/en
Priority claimed from US08/483,059 external-priority patent/US5840740A/en
Priority claimed from US08/487,443 external-priority patent/US5847172A/en
Priority claimed from US08/479,455 external-priority patent/US5994336A/en
Priority claimed from US08/483,057 external-priority patent/US5795885A/en
Application filed by Genaera Corp filed Critical Genaera Corp
Publication of PT832094E publication Critical patent/PT832094E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
PT96922490T 1995-06-07 1996-06-07 Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos PT832094E (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US08/476,855 US5874597A (en) 1995-06-07 1995-06-07 Certain aminosterol compounds and pharmaceutical compositions including these compounds
US08/475,572 US5840936A (en) 1995-06-07 1995-06-07 Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US08/479,457 US5763430A (en) 1995-06-07 1995-06-07 Method of treating a viral infection by administering a steroid compound
US08/483,059 US5840740A (en) 1995-06-07 1995-06-07 Aminosterol compounds and a method of treating infection using the aminosterol compounds
US08/487,443 US5847172A (en) 1995-06-07 1995-06-07 Certain aminosterol compounds and pharmaceutical compositions including these compounds
US08/479,455 US5994336A (en) 1995-06-07 1995-06-07 Method of inhibiting proliferation of cells by administering an aminosterol compound
US08/483,057 US5795885A (en) 1995-06-07 1995-06-07 Method of inhibiting profileration of cells by administering an aminosterol compound

Publications (1)

Publication Number Publication Date
PT832094E true PT832094E (pt) 2004-06-30

Family

ID=27569803

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96922490T PT832094E (pt) 1995-06-07 1996-06-07 Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos

Country Status (10)

Country Link
EP (2) EP0832094B1 (pt)
JP (2) JP4104164B2 (pt)
AT (1) ATE259375T1 (pt)
AU (1) AU723663C (pt)
CA (1) CA2223910C (pt)
DE (1) DE69631527T2 (pt)
DK (1) DK0832094T3 (pt)
ES (1) ES2216049T3 (pt)
PT (1) PT832094E (pt)
WO (1) WO1996040728A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
EP0910382B1 (en) * 1996-04-26 2003-06-11 Magainin Pharmaceuticals Inc. Squalamine in combination with other anti-cancer agents for treating tumors
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
WO1997044044A1 (en) * 1996-05-17 1997-11-27 Magainin Pharmaceuticals Inc. Therapeutic uses for an aminosterol compound
US7410959B1 (en) 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
AU5194998A (en) * 1996-11-01 1998-05-29 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and uses therefor
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
EP1274718B1 (en) 2000-04-12 2006-10-18 Genaera Corporation A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
WO2006119211A2 (en) * 2005-05-02 2006-11-09 Genaera Corporation Methods and compositions for treating ocular disorders
WO2007124086A1 (en) * 2006-04-21 2007-11-01 Genaera Corporation Induction of weight loss and the selective inhibition of ptp1b
EP2188299B1 (en) 2007-09-06 2017-10-25 Ohr Pharmaceutical, Inc. Compounds for treating diabetes
HUE026025T2 (en) 2008-05-09 2016-05-30 Merck Patent Gmbh A pharmaceutical composition comprising rimeporide for the treatment of diseases associated with beta cell dysfunction
PT2758060T (pt) 2011-09-19 2018-01-24 ETH Zürich Moduladores de ror gama para o tratamento de complicações de diabetes ii
MX367255B (es) * 2012-04-20 2019-08-12 Ohr Pharmaceutical Inc Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
CN110420211A (zh) 2013-03-15 2019-11-08 布莱阿姆青年大学 治疗炎症、自身免疫性疾病和疼痛的方法
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
US10441595B2 (en) * 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
FR3033563B1 (fr) * 2015-03-12 2018-04-13 Virbac Composes analogues de la squalamine utiles comme agents antibacteriens
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
MA50094A (fr) 2017-09-08 2020-07-15 Enterin Inc Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATING GUT-BRAIN AXIS DISORDERS
CN112782300B (zh) * 2020-12-25 2022-04-12 山东省食品药品检验研究院 一种胆烷酸的同分异构体及其检测方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192756A (en) * 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
AU6392894A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants

Also Published As

Publication number Publication date
WO1996040728A3 (en) 1997-03-27
JP2002515019A (ja) 2002-05-21
DE69631527D1 (de) 2004-03-18
CA2223910C (en) 2008-09-16
EP0832094A2 (en) 1998-04-01
AU6334996A (en) 1996-12-30
AU723663B2 (en) 2000-08-31
DE69631527T2 (de) 2004-09-23
ES2216049T3 (es) 2004-10-16
DK0832094T3 (da) 2004-05-17
EP1420027A2 (en) 2004-05-19
CA2223910A1 (en) 1996-12-19
EP0832094B1 (en) 2004-02-11
JP4104164B2 (ja) 2008-06-18
EP1420027A3 (en) 2012-01-04
ATE259375T1 (de) 2004-02-15
JP2007314577A (ja) 2007-12-06
AU723663C (en) 2001-11-01
WO1996040728A2 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
PT832094E (pt) Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos
ZA964819B (en) Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds.
IL115597A (en) Dihalopropene compounds and insecticidal/acaricidal compositions containing same
DK0943328T3 (da) Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
CA2186380A1 (en) Novel carbamates and ureas as modifiers of multi-drug resistance
DE69505490D1 (de) Dihalopropenverbindungen, sie enthaltende insektizide/akarizide mittel, und zwischenprodukte
DE69628019D1 (de) Chinolone und deren therapeutische verwendung
ES2137628T3 (es) Derivados de estilbeno y composiciones farmaceuticas que los contienen.
ATE225351T1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ES2179071T3 (es) Agentes vasodilatadores perifericos que comprenden como principio activo derivados de la piperidina 4-amino n-acilada.
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
AR001592A1 (es) Composicion herbicida y metodo de control de malezas
ZA964818B (en) Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds.
DK0679393T3 (da) Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol
DK0888323T3 (da) Dihydrobenzofuran og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel
TR199700452A2 (xx) B�cek ve zararl� kenelerin imhas�na mahsus maddeler.
ES2101373T3 (es) Tetrahidrociclopent(b)indol-metaminas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
ATE248830T1 (de) Substituierte 2,3-aryl-benzothiophene und ihre östrogene aktivität
DE19780042D2 (de) Therapeutische Mittel, enthaltend organische Selenverbindungen gegen Asthma
ATE141259T1 (de) N-substituierte carbonyloxyalkylpyrrol enthaltende insekticide, acarizide und molluskizide mittel
BR9911095A (pt) Compostos de amÈnios quartenário como agentes anti-tussìgenos
ECSP961819A (es) Nuevos inhibidores de farnesil-transferasa, su preparacion y las composiciones farmaceuticas que contienen (caso st 95042)